Recombinant oncolytic virus
US12351812B2 · kind B2 · utility
0Cited by
1References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 16, 2018 |
| Grant date | Jul 8, 2025 |
| Priority date | — |
| Expiry date | Sep 15, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/20043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Recombinant viral vectors are disclosed that contain a nucleic acid encoding a Second Mitochondria-derived Activator of Caspases (Smac) protein inserted within an RNA virus genome, wherein the Smac protein specifically binds to at least a portion of an Inhibitor of Apoptosis Protein (IAP). Also disclosed are methods of treating cancer using the disclosed vectors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.